Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.32 |
| ▸ | CTSL | P07711 | 3/20 | 0.32 |
| ▸ | CTSB | P07858 | 2/20 | 0.32 |
| ▸ | CTSS | P25774 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.31 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | RAD52 | P43351 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13128577 | 0.97 | CNR2 (0.36) | CNR2BDKRB1PTK2CTSLCTSB | |
| SCHEMBL186398 | 0.89 | HDAC1 (0.35) | CNR2BDKRB1PTK2CTSLCTSS | |
| SCHEMBL186154 | 0.89 | CNR2 (0.37) | CNR2BDKRB1PTK2CTSLCTSB | |
| SCHEMBL185785 | 0.88 | EPHX2 (0.41) | CNR2BDKRB1PTK2CTSLKDM4E | |
| SCHEMBL185963 | 0.88 | FPR2 (0.39) | CNR2BDKRB1PTK2CTSLCTSB | |
| SCHEMBL185691 | 0.87 | CNR2 (0.38) | CNR2BDKRB1PTK2CTSLCTSB | |
| SCHEMBL186861 | 0.87 | CNR2 (0.37) | CNR2BDKRB1PTK2CTSLCTSB | |
| SCHEMBL2806916 | 0.86 | CNR2 (0.37) | CNR2BDKRB1PTK2CTSLCTSB | |
| SCHEMBL2805326 | 0.86 | CNR2 (0.37) | CNR2BDKRB1PTK2CTSLCTSB | |
| SCHEMBL186671 | 0.86 | CNR2 (0.37) | CNR2BDKRB1PTK2CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | CNR2 882/4885BDKRB1 289/4885PTK2 3921/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | CNR2 882/4885BDKRB1 289/4885PTK2 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.